10 Jun 2026
Concord Biotech received USFDA approval for its tofacitinib tablets in 5 mg and 10 mg strengths, addressing a US market worth about 500 million dollars.
The arthritis and ulcerative-colitis drug marks Concord's push from fermentation-based APIs into finished formulations, a higher-margin segment that lifted its shares 6 percent on the news.